Clinical Investigation iDesign System With 1.3-PRESBY Treatment and STAR S4 IR™ Excimer Laser System
Study Details
Study Description
Brief Summary
A prospective study to evaluate the feasibility of a new treatment algorithm to increase depth of focus after wavefront-guided LASIK correction of myopic refractive errors with the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System. The purpose of this study is to determine whether wavefront-guided LASIK correction of myopic refractive errors with CustomVue combined with iDesign 1.3-PRESBY (presbyT-LASIK) treatments mitigate the effects of presbyopia by increasing the depth of focus compared to iDesign CustomVue treatments.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: iDesign 1.3-PRESBY iDesign 1.3-PRESBY in one eye of subject (experimental) is used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System. |
Device: iDesign 1.3-PRESBY treatment
Software used to calculate the LASIK treatment profile including a presbyopic correction component for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
|
Active Comparator: iDesign 1.3 iDesign 1.3 in one eye of subject (control) is used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System. |
Device: iDesign 1.3 treatment
Software used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
|
Outcome Measures
Primary Outcome Measures
- Monocular Distance Corrected Intermediate Visual Acuity (DCIVA) at 67 cm [6 months]
Mean distance corrected intermediate visual acuity (DCIVA) for presbyT-LASIK treatments (test) was compared to iDesign CustomVue treatments (control).
Secondary Outcome Measures
- Monocular Distance Corrected Near Visual Acuity (DCNVA) AT 40 cm [6 months]
Mean distance corrected near visual acuity (DCNVA) for PresbyT-LASIK treatments (test) was compared to iDesign CustomVue treatments (control).
Eligibility Criteria
Criteria
Inclusion Criteria:
All criteria apply to each eye
-
Signed informed consent and Personal Health Information Protection Act authorization.
-
At least 45 years of age at enrollment (date informed consent signed).
-
The refractive error, based on the iDesign displayed refraction selected for treatment ("4.0 Rx calc" at 12.5 mm), must be myopia with or without astigmatism with sphere up to -6.00 D, and cylinder between 0.00 D and -5.00 D with a maximum spherical equivalent (SE) of -8.00 D.
-
Require an add power of +1.00 D or more during near testing at 40 cm.
-
Anticipated stromal bed thickness of at least 250 microns based on preoperative central corneal pachymetry minus the maximum ablation depth (as calculated by the iDesign system) plus the intended flap thickness.
-
Distance Best Spectacle Corrected Visual Acuity (BSCVA) of 20/20 or better.
-
Uncorrected Visual Acuity (UCVA) of 20/40 or worse.
-
Less than or equal to 0.75 D difference between cycloplegic and manifest refraction sphere.
-
A stable refractive error (based on a previous exam, medical records, lensometry, or prescription at least 12 months prior to the preoperative manifest refraction), as defined by a change of ≤1.00 D in MRSE.
-
Any eye with a history of contact lens wear within the last 4 weeks must demonstrate refractive stability according to the following:
-
Rigid contact lenses (toric or spherical) must be removed for at least 4 weeks and soft contact lenses (toric or spherical) for at least 2 weeks prior to the first refraction used to establish stability.
-
Two consecutive refractions and keratometric readings must be conducted at least 7 days apart.
-
Refractive stability is defined as a change of not more than 0.50 D in manifest refraction sphere and cylinder as well as mean keratometry between measurements.
-
If the subject/eye meets the refractive stability criteria, contact lens wear is not permitted prior to surgery.
-
Agreement between manifest refraction (adjusted for optical infinity) and iDesign
System refraction chosen for treatment, as follows:
-
Spherical Equivalent: Magnitude of the difference is less than 0.625 D.
-
Cylinder: Magnitude of the difference is less than or equal to 0.5 D.
-
Cylinder Axis Tolerance: If either the manifest cylinder entered into the iDesign System or the iDesign cylinder selected for treatment is less than 0.5 D, there is no requirement for axis tolerance. When both cylinders have a magnitude of at least 0.5 D, the axis tolerance as determined by the iDesign system is linearly reduced from 15 (0.5 D) to 7.5 (7.0 D) based on the average magnitude of both cylinders. Note: If the axis tolerance is not in the calculated range, the iDesign system will produce a warning and this exam may not be used for treatment planning.
-
Willing and capable of complying with follow-up examinations for the duration of the study.
Exclusion Criteria:
-
Women who are pregnant, breast-feeding, intend to become pregnant, or are not using an adequate method of birth control [examples are any form of barrier contraception (such as condom or diaphragm with contraceptive cream/jelly), birth control pills, hormonal implant, IUD, abstinence or surgical sterilization (tubal ligation, hysterectomy or vasectomy)]. Note: Women who were pregnant or nursing may not be enrolled until 6 months after either delivery or have stopped nursing and there is documented refractive stability.
-
Concurrent use of systemic (including inhaled) medications that may impair healing, including but not limited to: antimetabolites, isotretinoin (Accutane®) within 6 months of treatment, and amiodarone hydrochloride (Cordarone®) within 12 months of treatment.
NOTE: The use of inhaled or systemic corticosteroids, whether chronic or acute, is deemed to adversely affect healing and subjects using such medications are specifically excluded from eligibility.
- History of any of the following medical conditions, or any other condition that could affect wound healing: collagen vascular disease, autoimmune disease, immunodeficiency diseases, ocular herpes zoster or herpes simplex, endocrine disorders (including, but not limited to unstable thyroid disorders and diabetes), lupus, and rheumatoid arthritis.
NOTE: The presence of diabetes (either type 1 or 2), regardless of disease duration, severity, or control, will specifically exclude subjects from eligibility.
-
Subjects with a cardiac pacemaker, implanted defibrillator or other implanted electronic device.
-
History of prior intraocular or corneal surgery (including cataract extraction), active ophthalmic disease or abnormality (including, but not limited to, symptomatic blepharitis, recurrent corneal erosion, dry eye syndrome, neovascularization > 1 mm from limbus), retinal detachment/repair, clinically significant lens opacity, clinical evidence of trauma, corneal opacity within the central 9 mm and visible on topography, at risk for developing strabismus, or with evidence of glaucoma or propensity for narrow angle glaucoma.
NOTE: Subjects with open angle glaucoma, regardless of medication regimen or control, or an IOP greater than 21 mmHg at screening, are specifically excluded from eligibility.
-
Evidence of keratoconus, corneal dystrophy or irregularity, or abnormal topography.
-
Known sensitivity or inappropriate responsiveness to any of the medications used in the postoperative course.
-
Desire to have monovision.
-
Intolerance to multifocal correction based on questionnaire responses to contact lens trial.
-
Participation in any other clinical study.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Image Plus Laser Eye Center | Winnipeg | Manitoba | Canada | R3C3J5 |
2 | University of Ottawa | Ottawa | Ontario | Canada | K1H 8L6 |
3 | Crystal Clear Vision | Toronto | Ontario | Canada | M5R 2E3 |
Sponsors and Collaborators
- Abbott Medical Optics
Investigators
- Study Director: Kendra Hileman, Abbott Medical Optics
Study Documents (Full-Text)
More Information
Publications
None provided.- STAR-116-TOPS
Study Results
Participant Flow
Recruitment Details | |
---|---|
Pre-assignment Detail | Per the protocol, the total number of participants enrolled is 42 (the number of participants who agreed to participate in the study and completed the informed consent process). The total number of participants Started is 7 (the number of participants who were assigned to each Arm/Group). |
Arm/Group Title | All Study Participants |
---|---|
Arm/Group Description | Parts of a participant were allocated to different interventions: Left side iDesign 1.3-PRESBY, Right side iDesign 1.3 Left Side iDesign 1.3, Right Side iDesign 1.3-PRESBY |
Period Title: Overall Study | |
STARTED | 7 |
COMPLETED | 6 |
NOT COMPLETED | 1 |
Baseline Characteristics
Arm/Group Title | All Study Participants |
---|---|
Arm/Group Description | Parts of a participant were allocated to different interventions: Left side iDesign 1.3-PRESBY, Right side iDesign 1.3 Left Side iDesign 1.3, Right Side iDesign 1.3-PRESBY |
Overall Participants | 7 |
Overall Eyes | 14 |
Age (Years) [Mean (Standard Deviation) ] | |
Mean (Standard Deviation) [Years] |
49.2
(3.3)
|
Sex: Female, Male (Count of Participants) | |
Female |
4
57.1%
|
Male |
3
42.9%
|
Race (NIH/OMB) (Count of Participants) | |
American Indian or Alaska Native |
0
0%
|
Asian |
1
14.3%
|
Native Hawaiian or Other Pacific Islander |
0
0%
|
Black or African American |
0
0%
|
White |
6
85.7%
|
More than one race |
0
0%
|
Unknown or Not Reported |
0
0%
|
Outcome Measures
Title | Monocular Distance Corrected Intermediate Visual Acuity (DCIVA) at 67 cm |
---|---|
Description | Mean distance corrected intermediate visual acuity (DCIVA) for presbyT-LASIK treatments (test) was compared to iDesign CustomVue treatments (control). |
Time Frame | 6 months |
Outcome Measure Data
Analysis Population Description |
---|
Due to the small sample size, descriptive results for all endpoints are provided along with confidence intervals, and no statistical conclusions are made. |
Arm/Group Title | iDesign 1.3-Presby Treatment (Experimental) | iDesign CustomVue Treatments (Control) |
---|---|---|
Arm/Group Description | One of subject's eye (experimental) treated with wavefront-guided LASIK correction of myopic refractive errors with the iDesign Advanced Wavescan Studio™ System with iDesign 1.3-PRESBY (presbyT-LASIK) treatments | One of subject's eye (control) treated with wavefront-guided LASIK correction of myopic refractive errors with the iDesign Advanced Wavescan Studio™ System with iDesign CustomVue treatments |
Measure Participants | 6 | 6 |
Measure Eyes | 6 | 6 |
Mean (95% Confidence Interval) [LogMAR] |
0.03
|
0.1
|
Title | Monocular Distance Corrected Near Visual Acuity (DCNVA) AT 40 cm |
---|---|
Description | Mean distance corrected near visual acuity (DCNVA) for PresbyT-LASIK treatments (test) was compared to iDesign CustomVue treatments (control). |
Time Frame | 6 months |
Outcome Measure Data
Analysis Population Description |
---|
Due to the small sample size, descriptive results for all endpoints are provided along with confidence intervals, and no statistical conclusions are made. |
Arm/Group Title | iDesign 1.3-Presby Treatment (Experimental) | iDesign CustomVue Treatments (Control) |
---|---|---|
Arm/Group Description | One of subject's eye (experimental) treated with wavefront-guided LASIK correction of myopic refractive errors with the iDesign Advanced Wavescan Studio™ System with iDesign 1.3-PRESBY (presbyT-LASIK) treatments | One of subject's eye (control) treated with wavefront-guided LASIK correction of myopic refractive errors with the iDesign Advanced Wavescan Studio™ System with iDesign CustomVue treatments |
Measure Participants | 6 | 6 |
Measure Eyes | 6 | 6 |
Mean (95% Confidence Interval) [LogMar] |
0.25
|
0.35
|
Adverse Events
Time Frame | 6 months | |
---|---|---|
Adverse Event Reporting Description | ||
Arm/Group Title | All Study Participants | |
Arm/Group Description | Parts of a participant were allocated to different interventions: Left side iDesign 1.3-PRESBY, Right side iDesign 1.3 Left Side iDesign 1.3, Right Side iDesign 1.3-PRESBY | |
All Cause Mortality |
||
All Study Participants | ||
Affected / at Risk (%) | # Events | |
Total | 0/7 (0%) | |
Serious Adverse Events |
||
All Study Participants | ||
Affected / at Risk (%) | # Events | |
Total | 0/7 (0%) | |
Other (Not Including Serious) Adverse Events |
||
All Study Participants | ||
Affected / at Risk (%) | # Events | |
Total | 2/7 (28.6%) | |
Eye disorders | ||
Diffuse lamellar keratitis | 1/7 (14.3%) | |
General disorders | ||
Mild Headache | 1/7 (14.3%) |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results.
Results Point of Contact
Name/Title | Priya Janakiraman |
---|---|
Organization | Johnson & Johnson Surgical Vision, Inc. |
Phone | 1 714 2478628 |
djanaki1@its.jnj.com |
- STAR-116-TOPS